Last reviewed · How we verify
Quadrivalent split influenza virus vaccine
This quadrivalent split influenza virus vaccine works by stimulating the body's immune system to produce antibodies against four different influenza viruses.
This quadrivalent split influenza virus vaccine works by stimulating the body's immune system to produce antibodies against four different influenza viruses. Used for Prevention of influenza disease caused by four different influenza viruses (two A viruses and two B viruses).
At a glance
| Generic name | Quadrivalent split influenza virus vaccine |
|---|---|
| Sponsor | Ab&B Bio-tech Co., Ltd.JS |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated influenza viruses that are split into their individual components, which are then used to stimulate an immune response. This immune response helps the body to recognize and fight off future infections caused by the same influenza viruses.
Approved indications
- Prevention of influenza disease caused by four different influenza viruses (two A viruses and two B viruses)
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Clinical Trials of Quadrivalent Influenza Vaccine (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: